SPYRE THERAPEUTICS, INC. Increase (Decrease) in Contract with Customer, Liability
SPYRE THERAPEUTICS, INC. (SYRE) reported Increase (Decrease) in Contract with Customer, Liability of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-02-19
- SPYRE THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2024-12-31 was $0.00.
- SPYRE THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2024-09-30 was $0.00.
- SPYRE THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- SPYRE THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2024-03-31 was $0.00.
- SPYRE THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for fiscal 2025 was $0.00.
- SPYRE THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- SPYRE THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for fiscal 2023 was $575.00K.
- SPYRE THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for fiscal 2022 was -$880.00K, a 124.61% decline from fiscal 2021.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-19 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-19 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $0.00 derived: sum of 3 quarters · filed 2026-02-19 | $0.00 10-K · filed 2026-02-19 |
| 2024-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2024-11-18 | $0.00 derived: sum of 2 quarters · filed 2024-11-18 | $0.00 10-Q/A · filed 2024-11-18 | $0.00 derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $0.00 derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18 | $0.00 10-Q/A · filed 2024-11-18 | $0.00 derived: sum of 3 quarters · filed 2026-02-19 | $0.00 derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $0.00 10-Q/A · filed 2024-11-18 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $0.00 derived: sum of 3 quarters · filed 2026-02-19 | $628.00K derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-19 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $628.00K derived: sum of 3 quarters · filed 2026-02-19 | $575.00K 10-K · filed 2026-02-19 |
| 2023-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2024-11-18 | $628.00K derived: sum of 2 quarters · filed 2024-11-18 | $575.00K 10-Q/A · filed 2024-11-18 | $592.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $628.00K derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18 | $575.00K 10-Q/A · filed 2024-11-18 | $592.00K derived: sum of 3 quarters · filed 2025-02-27 | $609.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$53.00K 10-Q/A · filed 2024-11-18 | -$36.00K derived: sum of 2 quarters · filed 2025-02-27 | -$19.00K derived: sum of 3 quarters · filed 2025-02-27 | -$166.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $34.00K derived: sum of 2 quarters · filed 2025-02-27 | -$113.00K derived: sum of 3 quarters · filed 2025-02-27 | -$880.00K 10-K · filed 2025-02-27 |
| 2022-09-30 | $17.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$130.00K derived: sum of 2 quarters · filed 2023-11-09 | -$897.00K 10-Q · filed 2023-11-09 | -$3.73M derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-06-30 | -$147.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$914.00K 10-Q · filed 2023-08-11 | -$3.74M derived: sum of 3 quarters · filed 2024-11-18 | -$5.14M derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-03-31 | -$767.00K 10-Q · filed 2023-05-11 | -$3.60M derived: sum of 2 quarters · filed 2024-11-18 | -$5.00M derived: sum of 3 quarters · filed 2024-11-18 | -$18.69M derived: sum of 4 quarters · filed 2024-11-18 |
| 2021-12-31 | -$2.83M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-11-18 | -$4.23M derived: sum of 2 quarters · filed 2024-11-18 | -$17.92M derived: sum of 3 quarters · filed 2024-11-18 | $3.58M 10-K/A · filed 2024-11-18 |
| 2021-09-30 | -$1.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$15.10M derived: sum of 2 quarters · filed 2022-11-03 | $6.41M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | -$13.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $7.80M 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $21.50M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-02 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-03-08 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $0.00 derived: sum of 2 quarters · filed 2021-03-18 | $0.00 derived: sum of 3 quarters · filed 2021-03-18 | -$20.00K 10-K · filed 2021-03-18 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $0.00 derived: sum of 2 quarters · filed 2019-11-06 | -$20.00K 10-Q · filed 2019-11-06 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$20.00K 10-Q · filed 2019-08-06 | ||
| 2018-03-31 | -$20.00K 10-Q · filed 2019-05-07 | |||
| 2017-12-31 | -$51.00K 10-K · filed 2020-02-24 | |||
| 2016-12-31 | $71.00K 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |